Title
Association of hypothyroidism with outcomes in hospitalized adults with COVID-19: Results from the International SCCM Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry
Date Issued
01 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Bogojevic M.
Bansal V.
Pattan V.
Singh R.
Tekin A.
Sharma M.
La Nou A.T.
LeMahieu A.M.
Hanson A.C.
Schulte P.J.
Deo N.
Qamar S.
Zec S.
Valencia Morales D.J.
Perkins N.
Kaufman M.
Denson J.L.
Melamed R.
Banner-Goodspeed V.M.
Christie A.B.
Tarabichi Y.
Heavner S.
Kumar V.K.
Walkey A.J.
Gajic O.
Bhagra S.
Kashyap R.
Lal A.
Mayo Clinic
Publisher(s)
John Wiley and Sons Inc
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is associated with high rates of morbidity and mortality. Primary hypothyroidism is a common comorbid condition, but little is known about its association with COVID-19 severity and outcomes. This study aims to identify the frequency of hypothyroidism in hospitalized patients with COVID-19 as well as describe the differences in outcomes between patients with and without pre-existing hypothyroidism using an observational, multinational registry. Methods: In an observational cohort study we enrolled patients 18 years or older, with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection between March 2020 and February 2021. The primary outcomes were (1) the disease severity defined as per the World Health Organization Scale for Clinical Improvement, which is an ordinal outcome corresponding with the highest severity level recorded during a patient's index COVID-19 hospitalization, (2) in-hospital mortality and (3) hospital-free days. Secondary outcomes were the rate of intensive care unit (ICU) admission and ICU mortality. Results: Among the 20,366 adult patients included in the study, pre-existing hypothyroidism was identified in 1616 (7.9%). The median age for the Hypothyroidism group was 70 (interquartile range: 59–80) years, and 65% were female and 67% were White. The most common comorbidities were hypertension (68%), diabetes (42%), dyslipidemia (37%) and obesity (28%). After adjusting for age, body mass index, sex, admission date in the quarter year since March 2020, race, smoking history and other comorbid conditions (coronary artery disease, hypertension, diabetes and dyslipidemia), pre-existing hypothyroidism was not associated with higher odds of severe disease using the World Health Organization disease severity index (odds ratio [OR]: 1.02; 95% confidence interval [CI]: 0.92, 1.13; p =.69), in-hospital mortality (OR: 1.03; 95% CI: 0.92, 1.15; p =.58) or differences in hospital-free days (estimated difference 0.01 days; 95% CI: −0.45, 0.47; p =.97). Pre-existing hypothyroidism was not associated with ICU admission or ICU mortality in unadjusted as well as in adjusted analysis. Conclusions: In an international registry, hypothyroidism was identified in around 1 of every 12 adult hospitalized patients with COVID-19. Pre-existing hypothyroidism in hospitalized patients with COVID-19 was not associated with higher disease severity or increased risk of mortality or ICU admissions. However, more research on the possible effects of COVID-19 on the thyroid gland and its function is needed in the future.
Language
English
Subjects
Scopus EID
2-s2.0-85129326796
PubMed ID
Source
Clinical Endocrinology
ISSN of the container
03000664
Sponsor(s)
The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry Investigator Group members are listed in Supplemental Appendix 1. This publication was supported by NIH/NCRR/NCATS CTSA Grant Number UL1 TR002377. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The registry is funded in part by the Gordon and Betty Moore Foundation and Janssen Research & Development, LLC. They had no influence on the analysis, interpretation and reporting of pooled data. Allan J. Walkey receives funding from the National Institutes of Health/National Heart, Lung and Blood Institute Grants, R01HL151607, R01HL139751 and R01HL136660, Agency of Healthcare Research and Quality, R01HS026485, Boston Biomedical Innovation Center/NIH/NHLBI 5U54HL119145‐07. Ognjen Gajic receives funding from the Agency of Healthcare Research and Quality, R18HS 26609‐2, National Institutes of Health/National Heart, Lung and Blood Institute, R01HL 130881 and UG3/UH3HL 141722; Department of Defense, DOD W81XWH; American Heart Association Rapid Response Grant—COVID‐19. Rahul Kashyap receives funding from the National Institutes of Health/National Heart, Lung and Blood Institute: R01HL 130881, UG3/UH3HL 141722; Gordon and Betty Moore Foundation and Janssen Research & Development, LLC. They had no influence on the acquisition, analysis, interpretation and reporting of pooled data for this manuscript. Joshua L. Denson receives funding in part from the American Diabetes Association COVID‐19 Research Award (7–20‐COVID‐053), the Society of Critical Care Medicine, the Gordon and Betty Moore Foundation, National Institutes of Health Awards (U54 GM104940), which funds the Louisiana Clinical and Translational Science Center Roadmap Scholars Award. Vishakha K. Kumar received funding from the Gordon and Betty Moore Foundation, Janssen Research & Development, LLC and CDC Foundation. They had no influence on the acquisition, analysis, interpretation and reporting of pooled data for this manuscript.
Sources of information:
Directorio de Producción Científica
Scopus